Alcon Management

Management Kriterienprüfungen 3/4

Alcon CEO ist David Endicott , ernannt in Jul 2018, hat eine Amtszeit von 6.33 Jahren. Die jährliche Gesamtvergütung beträgt $12.33M , bestehend aus 10.7% Gehalt und 89.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.047% der Aktien des Unternehmens, im Wert von CHF17.76M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

David Endicott

Geschäftsführender

US$12.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	10.7%
Amtszeit als Geschäftsführer	6.3yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Endicott im Vergleich zu den Einnahmen von Alcon verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$12m	US$1m	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD12.33M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.72M).

Entschädigung vs. Einkommen: DavidDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

David Endicott (59 yo)

6.3yrs

Amtszeit

US$12,325,391

Vergütung

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% CHF 4.3m
David Endicott	CEO & Director	6.3yrs	US$12.33m	0.047% CHF 17.8m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% CHF 441.2k
Timothy Stonesifer	Senior VP & CFO	5.6yrs	keine Daten	0.020% CHF 7.4m
Ian Bell	Senior VP & COO	less than a year	keine Daten	0.0081% CHF 3.1m
Margaret Buckley	Chief Accounting Officer	no data	keine Daten	keine Daten
Franck Leveiller	SVP of Global Research & Development and Chief Scientific Officer	2.4yrs	keine Daten	keine Daten
Royce Bedward	Senior VP	no data	keine Daten	keine Daten
Kimberly Martin	Senior VP	4.3yrs	keine Daten	keine Daten
Laurent Attias	SVP of Corporate Strategy	no data	keine Daten	0.0040% CHF 1.5m
Leon Sergio Fraustro	Senior VP & President of Americas	9.3yrs	keine Daten	0.0043% CHF 1.6m
Ed McGough	Senior VP and Head of Global Manufacturing & Technical Operations	no data	US$2.03m	keine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrenes Management: 0A0DDas Führungsteam des Unternehmens gilt als erfahren (5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% CHF 4.3m
David Endicott	CEO & Director	5.8yrs	US$12.33m	0.047% CHF 17.8m
Arthur Cummings	Executive Director	5.8yrs	US$284.68k	0.0012% CHF 441.2k
Karen May	Independent Director	5.8yrs	US$325.52k	0.0052% CHF 1.9m
D. Grossman	Independent Vice Chair	5.8yrs	US$361.69k	0.0031% CHF 1.2m
Thomas Glanzmann	Independent Director	5.8yrs	US$352.98k	0.0041% CHF 1.6m
Dieter Spälti	Independent Director	5.8yrs	US$236.83k	0.0049% CHF 1.8m
Scott Maw	Independent Director	5.8yrs	US$333.87k	0.0031% CHF 1.2m
Lynn Bleil	Independent Director	5.8yrs	US$296.31k	0.0019% CHF 735.3k
Ines Pöschel	Independent Director	5.8yrs	US$293.86k	0.0021% CHF 799.4k
RaQuel Bono	Independent Director	2.6yrs	US$256.66k	0.00056% CHF 211.2k

5.8yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: 0A0DDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Alcon Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Alcon Announces Management Changes

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc., Annual General Meeting, May 05, 2023

Insufficient new directors

Insufficient new directors

Alcon Inc., Annual General Meeting, Apr 28, 2021

Recent updates

Third quarter 2024 earnings released: EPS: US$0.53 (vs US$0.41 in 3Q 2023)

Alcon Inc. Revises Earnings Guidance for the Year 2024

Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: US$0.45 (vs US$0.34 in 2Q 2023)

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 22% undervalued

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings released: EPS: US$0.50 (vs US$0.35 in 1Q 2023)

Upcoming dividend of CHF0.24 per share

Alcon Inc. Approves Gross Dividend

Now 20% undervalued

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings released: EPS: US$1.98 (vs US$0.68 in FY 2022)

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.24 in 3Q 2022)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.35 (vs US$0.34 in 1Q 2022)

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Full year 2022 earnings released: EPS: US$0.68 (vs US$0.77 in FY 2021)

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Now 20% undervalued after recent price drop

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: EPS: US$0.30 (vs US$0.31 in 2Q 2021)

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.17 in 1Q 2021)

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon Continues Its Successful Rollout of Precision1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Third quarter 2021 earnings released: EPS US$0.004 (vs US$0.30 loss in 3Q 2020)

President of Global Business & Innovation Michael Onuscheck has left the company

Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.86 loss in 2Q 2020)

Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens

First quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 loss in 1Q 2020)

Alcon Inc. Provides Earnings Guidance for the Full Year 2021

Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S

Full year 2020 earnings released: US$1.09 loss per share (vs US$1.34 loss in FY 2019)

Revenue beats expectations

Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S

Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S

Alcon Inc. Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S

Alcon Inc., Annual General Meeting, Apr 28, 2021

Alcon Canada Introduces AcrySof IQ Vivity, the Only Presbyopia-Correcting Intraocular Lens with X-WAVE Technology